Quantum BioPharma Appoints Leading MS Expert to Guide Development of Novel Demyelination Inhibitor

Quantum BioPharma Ltd. has appointed Dr. Jack Antel, a world-renowned multiple sclerosis expert and Professor of Neurology at McGill University, as clinical advisor to support development of Lucid-21-302, the company's patented investigational drug designed to inhibit demyelination in MS. Dr. Antel, who received the National Multiple Sclerosis Society and American Academy of Neurology's Dystel Award and has authored over 450 published articles, will guide the design of efficacy trials as Quantum advances Lucid-MS into Phase 2 studies.

The appointment of Dr. Antel represents a significant strengthening of Quantum BioPharma's clinical expertise as the company prepares for advanced clinical testing of its lead compound. Dr. Antel joins Dr. Peter Stys, Professor of Neurosciences at the University of Calgary, who continues to serve as clinical advisor, creating a formidable team of neurological experts to oversee the drug's development pathway. This strategic move comes at a critical juncture as Lucid-MS transitions from preclinical validation to human trials.

Lucid-MS is a patented new chemical entity that has demonstrated the ability to prevent and reverse myelin degradation in preclinical models. Myelin degradation represents the underlying mechanism of multiple sclerosis, making this therapeutic approach potentially transformative for the approximately 2.8 million people worldwide living with the condition. The drug's mechanism of action targets the fundamental pathology of MS rather than merely managing symptoms, positioning it as a potential disease-modifying treatment.

Quantum BioPharma maintains a diverse portfolio of strategic investments through its wholly owned subsidiary FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. The company also retains ownership of 20.11% of Unbuzzd Wellness Inc. as of March 31, 2025, under an agreement that includes royalty payments of 7% of sales from unbuzzd until payments to Quantum BioPharma total $250 million, after which the royalty drops to 3% in perpetuity. Additional information about the company is available at https://ibn.fm/QNTM.

The progression of Lucid-MS into Phase 2 trials under the guidance of leading MS specialists signals an important milestone in the development of novel therapies for neurodegenerative conditions. With multiple sclerosis affecting millions globally and current treatments primarily focused on symptom management and reducing relapse rates, a therapy that addresses the core mechanism of myelin degradation could represent a significant advancement in neurological care. The involvement of internationally recognized experts like Dr. Antel provides additional credibility to the scientific approach and increases confidence in the trial design as the program moves forward.